upndown1313

Big Pharma: Where's the Risk Management?

Sorry not impressed, either with oral-Lyn data that has been presented or the concept of a metformin chewing gum. Based on PhII results, PhIII will not get approval fro Oral-Lyn. Sorry, but this is a scam company at best. Not reckless, but a realist.


On Jul 07 06:51 PM Oil wrote:

> Generex has additional factors in it's favor. It's bioequivalent
> study has shown their "Metcontrol" chewing gum to be interchangeable
> with Metformin tablets. Article here; finance.yahoo.com/news...;.v=1
> Metformin according to research is the 2nd most prescribed drug for
> type 2 diabetes. Generex plans to begin applying for approval in
> first quarter 2010. Also the wholly owned subsidiary Antigen Express
> claims to currently have the technology to vastly out produce the
> traditional method of vaccine production. Article; www.telegram.com/artic...
>
>
> To upndown1313, This article does not compare Generex to Pfizer.
> The article simply suggests an opportunity for a big company to buy
> or license from Generex. And mentions the big company's failures
> in the insulin market. Also it's probably reckless to say Oral-Lyn
> will "never" get approval in a major market because the delivery
> method is highly variable and unreliable. If clinical trials are
> going well then it's hard (foolish?) to argue with results.

Big Pharma: Where's the Risk Management?

GNBT is about as highly speculative as you can get. Right up there with the likes of GNTA et al. Oral-Lyn will never get approval in a major martket. Absorption is highly variable and unreliable. I agree that Big Pharma is stumbling around in this environment, but comparing this joke of a company called Generex to PFE is absolutely ludicrous. This begs the question, where is your risk management or are you just clueless?